GTBP — GT Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 109657 ·
Last close
$6.89
Market Cap
$12.43M
52W High
$11.98
52W Low
$0.22
ADV30
352,280
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -2,848,000 | -2,833,000 | 9,996,000 | 8,923,000 | 2,416,000 |
| Dec 2025 | 0 | — | -5,595,000 | -23,031,000 | 8,106,000 | 6,811,000 | 2,319,000 |
| Sep 2025 | 0 | — | -3,382,000 | 8,299,000 | 4,321,000 | 2,528,000 | 1,321,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,180,000
Investing CF
$0
Financing CF
$19,739,000
CapEx
—
Dividends Paid
$-144,000
Buybacks
—
EPS Diluted TTM
$-10.32
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-726,837,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-29,065,000
Pretax Income TTM
$-47,734,000
Interest Exp TTM
$63,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -12,422,000 | -28,354,000 | 8,106,000 | 2,319,000 | 5,787,000 | -12,914,000 |
| Dec 2024 | 0 | -14,364,000 | -13,162,000 | 4,232,000 | 5,902,000 | -1,670,000 | -12,904,000 |
| Dec 2023 | 0 | -13,576,000 | -7,597,000 | 14,109,000 | 6,633,000 | 7,476,000 | -8,852,000 |
| Dec 2022 | 0 | -21,257,000 | -20,884,000 | 16,736,000 | 5,002,000 | 11,734,000 | -15,217,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-10.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADIL | ADIAL PHARMACEUTICALS, INC. | $12.38M | $4.22 | — |
| BFRG | BullFrog AI Holdings, Inc. | $12.35M | $0.67 | — |
| BLRX | BioLineRx Ltd. | $12.61M | $2.60 | — |
| VTGN | Vistagen Therapeutics, Inc. | $11.98M | $0.27 | — |
| QNRX | Quoin Pharmaceuticals Ltd. | $12.91M | $6.43 | — |
News headlines (Yahoo Finance, 1h cache)
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
2026-09-16 11:30 · Yahoo
GT Biopharma Reports Second Quarter 2026 Financial Results
2026-08-14 12:00 · Yahoo
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
2026-06-01 11:31 · Yahoo
GT Biopharma Reports First Quarter 2026 Financial Results
2026-05-15 12:00 · Yahoo
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
2026-05-14 12:16 · Yahoo
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
2026-09-15 13:15 · Yahoo
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
2026-09-11 12:00 · Yahoo
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
2026-06-01 12:00 · Yahoo
RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation
2026-04-10 16:55 · Yahoo
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
2026-05-14 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.